Quality of Life and Patient Satisfaction inPatients with Atrial Fibrillation on Stable Vitamin K Antagonist Treatment or Switched to a non-Vitamin K Antagonist Oral Anticoagulant during a 1-year follow-up: A PREFER in AF Registry Substudy.

0492389 - ÚI 2019 FR eng J - Článek v odborném periodiku
De Caterina, R. - Brüggenjürgen, B. - Darius, H. - Köhler, S. - Lucerna, M. - Pecen, Ladislav - Renda, G. - Schilling, R. J. - Schliephacke, T. - Zamorano, J. - Le Heuzey, J.Y. - Kirchhof, P.
Quality of Life and Patient Satisfaction inPatients with Atrial Fibrillation on Stable Vitamin K Antagonist Treatment or Switched to a non-Vitamin K Antagonist Oral Anticoagulant during a 1-year follow-up: A PREFER in AF Registry Substudy.
Archives of Cardiovascular Diseases. Roč. 111, č. 2 (2018), s. 74-84. ISSN 1875-2136. E-ISSN 1875-2128
Klíčová slova: Antagonist oral anticoagulants * Antivitamine K * Atrial fibrillation * Changement de traitement * Non-vitamin K * Patient satisfaction * Quality of life * Switching * Vitamin K antagonists
Impakt faktor: 2.355, rok: 2018

BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are being introduced for stroke prevention in non-valvular Atrial Fibrillation (AF), and promise to be accepted better than Vitamin K Antagonists (VKAs) by patients, improving their Quality of Life (QoL). AIM: To assess to what extent patient-related factors influence decisions to switch from a VKA to a NOAC. METHODS: The PREFER in AF Registry collected data at baseline in 2012 - at the beginning of NOAC prescriptions - and at 1-year follow-up, in 6412 patients in seven Western European countries. QoL and patient satisfaction questionnaires (EQ-5D-5L and/or PACT-Q2) were completed in 3777 patients at both visits. Data were compared across categories of patients on stable treatment with a VKA (i.e. continuously over the previous 12 months) (n=2102) or recently switched (within 12 months) from a VKA to a NOAC (n=213) during a 1-year follow-up, allowing a snapshot of factors influencing the switch at a time when NOACs were being introduced into the market. RESULTS: Compared to patients on stable treatment with a VKA, switched patients were similar in terms of age, sex, body mass index and other risk factors, but had lower prevalences of hypertension and heart valve dysfunction, and a lower rate of use of concomitant treatment with antiplatelet/anti-inflammatory agents; they also had a lower CHA2DS2-VASc score. Among 25 features investigated, switched patients more often reported bruising or bleeding, complained about bruising, were dissatisfied with the anticoagulant treatment, and reported mobility problems and anxiety/depressive traits. CONCLUSIONS: At the beginning of NOAC prescriptions, European doctors tended to switch from VKAs to NOACs those patients at lower risk than "non-switchers". Complaints about bruising or bleeding, dissatisfaction with treatment, mobility problems and anxiety/depression traits appear to be related to - and may have influenced - the choice to switch from a VKA to a NOAC.
Trvalý link: http://hdl.handle.net/11104/0285949